To the authors' knowledge, few population-based studies to date have evaluated the association between location of care, complications with induction therapy, and early mortality in patients with acute myeloid leukemia (AML). METHODS: Using linked data from the California Cancer Registry and Patient Discharge Dataset (1999-2014), the authors identified adult (aged 18 years) patients with AML who received inpatient treatment within 30 days of diagnosis. A propensity score was created for treatment at a National Cancer Institute-designated cancer center (NCI-CC). Inverse probability-weighted, multivariable logistic regression models were used to determine associations between location of care, complications, and early mortality (death 60 days from diagnosis). RESULTS: Of the 7007 patients with AML, 1762 (25%) were treated at an NCI-CC. Patients with AML who were treated at NCICCs were more likely to be aged 65 years, live in higher socioeconomic status neighborhoods, have fewer comorbidities, and have public health insurance. Patients treated at NCI-CCs had higher rates of renal failure (23% vs 20%; P 5 .010) and lower rates of respiratory failure (11% vs 14%; P 5 .003) and cardiac arrest (1% vs 2%; P 5 .014). After adjustment for baseline characteristics, treatment at an NCI-CC was associated with lower early mortality (odds ratio, 0.46; 95% confidence interval, 0.38-0.57). The impact of complications on early mortality did not differ by location of care except for higher early mortality noted among patients with respiratory failure treated at non-NCI-CCs. CONCLUSIONS: The initial treatment of adult patients with AML at NCI-CCs is associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. Lower early mortality may result from differences in hospital or provider experience and supportive care. Cancer 2018;124:1938-45.
INTRODUCTION
Acute myeloid leukemia (AML) is the one of the most common leukemias in adults and is associated with a poor overall prognosis. 1 The initial standard treatment of AML consists of induction chemotherapy that usually requires an inpatient hospitalization of at least 1 month, a period that is associated with a high early mortality rate of 12% to 26% due to the underlying disease and complications of treatment. [2] [3] [4] Early mortality, or death within 30 to 60 days of diagnosis, has improved over the last 40 years largely due to advances in supportive care, including the treatment of infections and rigorous transfusions, 5, 6 but there continue to be disparities in outcomes between specific groups. 7, 8 We previously observed that race/ethnicity, neighborhood socioeconomic status (SES), marital status, and location of care impacted early mortality in patients with AML. 9 Recent research among patients with solid tumors has highlighted the impact of the cancer care delivery setting on patient outcomes. In patients with lung, prostate, breast, and colorectal cancer, treatment at specialty cancer hospitals compared with community centers was associated with improved 1-year mortality after adjustment for cancer stage. 10 In addition, patients undergoing cancer surgery for lung, gastrointestinal, and bladder cancers have been shown to experience reduced surgical and late mortality rates when treated at National Cancer Institute-designated cancer centers (NCI-CCs) rather than community hospitals. [11] [12] [13] To the best of our knowledge, few studies to date have evaluated the association between location of care and outcomes in patients with hematological malignancies, including AML. One recent study demonstrated that adolescents and young adults with acute lymphoblastic leukemia and AML treated at NCI-CCs or Children's Oncology Group sites had better survival compared with those treated elsewhere. However, this study was limited to facilities in Los Angeles county and did not consider early mortality. 14 In a previous report, we demonstrated that early complications and early mortality were lower for patients with AML who were treated at NCI-CCs; however, that report did not examine potential reasons for this disparity, nor use more robust analytical methods to mitigate the inherent selection bias, in which patients receive treatment at an NCI-CC. 9 In the current study, we examined differences in the sociodemographic and clinical characteristics of patients with AML who were treated at NCICCs versus non-NCI-CCs. We also evaluated the impact of hospital type on early mortality while controlling for these differences and examined whether complications during initial therapy by location of care impact early mortality. We hypothesized that patients with AML who were treated at NCI-CCs would have lower rates of complications related to induction therapy and lower early mortality compared with those treated elsewhere.
MATERIALS AND METHODS

Databases
The current study used a linked database between the California Cancer Registry (CCR) and the California Office of Statewide Health Planning and Development Patient Discharge Database (PDD). The CCR contains sociodemographic, clinical, and pathologic information regarding nearly all patients diagnosed with cancer in California. Reporting is mandatory and completeness of cases is at least 98%. 15 From the CCR, information regarding age at the time of diagnosis, race/ethnicity, year of diagnosis, sex, marital status, neighborhood SES, health insurance at diagnosis or initial treatment, date of initial chemotherapy, and vital status complete through 2014 was obtained. 1 The PDD contains information regarding all patients hospitalized in California, except patients admitted to 1 of 14 federal hospitals (12 Veterans Affairs hospitals and 2 military hospitals). Serial records from a single individual are linked using an encrypted form of their social security number, called the record linkage number. 16, 17 PDD records include a principal medical diagnosis, up to 24 additional "secondary" diagnoses, and a principal and up to 20 secondary procedures coded using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. From the PDD, we obtained information regarding chemotherapy administration, leukapheresis (a procedure used as a surrogate for a diagnosis of hyperleukocytosis; code 99.72), and comorbidities up to 2 years before or at the time of first admission for AML using the Elixhauser Index. 18 We also were able to obtain information regarding complications, which were included if they occurred within any hospitalization from the time of diagnosis to 60 days, or death. Complications determined included: major bleeding, sepsis, venous thrombosis, renal failure, liver dysfunction, respiratory failure, or cardiac arrest (see Supporting Table 1 for ICD-9-CM codes). These complications were chosen because they have been identified previously as being common complications during AML induction treatment. 3 The database also includes a hospital identifier. From this list of hospitals, we were able to classify hospitals into those associated with 1 of the 8 NCI-CCs in California. All other hospitals were classified as non-NCI-CCs.
Study Population
Adult patients (those aged 18 years) diagnosed with a first primary AML and treated with chemotherapy at a hospital in California from 1999 through 2014 were eligible for the current study. To identify cases of AML, we used the following morphology codes from the World Health Organization's International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3): 9840, 9861, 9865, 9867, 9869 to 9874, 9891, 9895 to 9898, 9910, 9911, 9920, and 9931. We excluded patients with a diagnosis of acute promyelocytic leukemia because the treatment and management differs from those for AML. In addition, we excluded patients without a record linkage number to hospital data, patients with an AML diagnosis made at autopsy or on the death certificate only, patients who did not receive chemotherapy within 30 days of diagnosis, and those without an inpatient hospitalization or known hospital type (Fig. 1) . 
Statistical Analysis
The differences in baseline characteristics and complications by location of care (NCI-CC vs non-NCI-CC facilities) were assessed using chi-square tests. Propensity score methodology was used to balance the baseline covariates between patients treated at an NCI-CC and those treated at non-NCI-CC facilities.
Multivariable logistic regression was used to estimate propensity scores for the location of care variable (NCI-CC/non-NCI-CC facilities), predicted from baseline characteristics: age, sex, race/ethnicity, year of diagnosis, marital status, neighborhood SES, health insurance type, and number of medical comorbidities (see Supporting Fig. 1) . To obtain groups similar with regard to baseline characteristics between those treated at NCI-CCs and non-NCI-CCs, inverse probability weighting was used in the multivariable models for mortality. The quality of the propensity scores estimated was evaluated using 2 types of comparisons: comparing the distributions of propensity scores across the 2 groups (NCI-CC/non-NCI-CC facilities) and comparing the distribution of each covariate across the 2 groups. Furthermore, the standardized mean differences in baseline characteristics between the NCI-CC and non-NCI-CC groups were used to determine the effectiveness of the propensity score adjustment.
The primary outcome was death within 60 days (early mortality) from the time of AML diagnosis. Inverse probability-weighted multivariable logistic regression models were used to determine associations between location of care and complications with early mortality, adjusting for baseline patient characteristics. Interactions of complications and location of care with early mortality also were determined for each covariate in the model. Analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina) and a 2-sided P value <.05 was considered to be statistically significant, including interactions.
RESULTS
Of a total of 13,413 adult patients with first primary AML, we identified 7007 patients who fulfilled our inclusion criteria (Fig. 1 Differences in complication rates within 60 days of a diagnosis of AML between patients treated at NCI-CCs versus non-NCI-CCs are described in Table 3 . Leukapheresis occurred more frequently among patients treated at NCI-CCs (5.5% vs 2.7%; P<.001). Patients treated at NCI-CCs had higher rates of renal failure (22.8% vs 19.9%; P 5 .010), but lower rates of respiratory failure (11.6% vs 14.3%; P 5 .003) and cardiac arrest (1.1% vs 2.0%; P 5 .014) compared with patients treated at non-NCI-CCs. At 60 days after diagnosis, more patients treated at NCI-CCs were alive (88.0% vs 76.3%; P<.001). Other complications did not significantly differ by location of care.
Early mortality among patients with AML improved over time at both NCI-CCs and non-NCI-CCs (Fig. 2) . However, throughout the study period, patients treated at NCI-CCs were found to have a persistently lower early mortality rate (average, 12%) compared with those treated at non-NCI-CCs (average, 24%).
After inverse probability weighting and adjustment for sociodemographic factors, comorbidities, and complications, treatment at an NCI-CC was associated with significantly lower early mortality compared with treatment at a non-NCI-CC (OR, 0.46; 95% CI, 0.40-0.54) (Table 4). Complications associated with increased early mortality included major bleeding; liver, renal, and respiratory failure; and cardiac arrest. The impact of complications on early mortality did not appear to differ by location of care, with the exception of respiratory failure (P for interaction 5 .009) and thrombosis (P for interaction 5 .034). Patients with AML with respiratory failure had higher odds of early mortality when treated at non-NCICCs (OR, 9.48; 95% CI, 7.06-12.74) versus NCI-CCs (OR, 4.20; 95% CI, 2.61-6.78). Although the association between thrombosis and early mortality differed between NCI-CCs and non-NCI-CCs, neither association reached statistical significance (Table 4) . Similar results were observed in the traditional multivariate model (see Supporting Table 2 ).
DISCUSSION
In the current analysis using a large and diverse cohort of hospitalized patients with AML who were receiving initial chemotherapy, treatment at NCI-CCs was found to be associated with a 53% reduction in the odds of early mortality compared with treatment at non-NCI-CCs. This association persisted in propensity-weighted analyses adjusted for sociodemographic factors, comorbidities, and complications. We did not find substantial differences in the rates of complications by location of care, except that patients treated at NCI-CCs had higher rates of renal failure and lower rates of respiratory failure and sepsis. Although the majority of complications were associated with increased early mortality, patients with respiratory failure had worse outcomes when treated at a non- Abbreviations: AML, acute myeloid leukemia; NCI-CC, National Cancer Institute-designated cancer center. a Derived using the chi-square test.
NCI-CCs. We believe the results of the current study add to the growing body of research that suggests that access to, and type of, hospital may impact cancer outcomes. 19, 20 Although there have been many successful advances in the care and support of patients with AML, the current study findings of such striking variation in early mortality outcomes by cancer care setting suggest that these advances may not have disseminated across all treatment settings. This is supported by the conclusion of a recent Institute of Medicine report that the cancer care system is in crisis, with inconsistencies in the quality of care being delivered to patients. 21 Further research should evaluate specific differences in the care provided to patients with AML who are hospitalized at NCI-CCs compared with other facilities to implement policies and practices that will ensure that all patients receive high-value and effective care. The NCI-CC designation specifically requires depth and breadth in clinical and basic science research and population sciences, cancer prevention programs, and wideranging clinical resources. Recent research has suggested that the designation also may serve as a benchmark with which to assess the quality of cancer care. 10, 11, 22, 23 There are many potential reasons to explain the decreased early mortality noted for patients treated at NCI-CCs. It has been reported that high-volume centers such as NCI-CCs may have better expertise at performing specialized care compared with low-volume non-NCICCs. 13, [24] [25] [26] In the current study, NCI-CCs saw a median of 13 patients with AML annually whereas non-NCI-CCs saw a median of only 2 patients. A recent study demonstrated reduced inpatient mortality rates among patients with AML treated at high-volume versus low-volume centers. 27 High-volume centers, defined as those in the highest quartile of the annual number of patients with AML admitted for chemotherapy, had an inpatient mortality rate of 1.59% compared with 4.97% in low-volume centers (those in the lowest quartile). High-volume centers may have greater hospital resources, including advanced intensive care units, lower nurse staffing ratios, and more diagnostic capabilities, factors that have been speculated to account for part of the mortality differences noted in surgical procedures. 28, 29 Differences in health care delivery practices between institutions also may play a role in outcomes. Prior studies have noted substantial hospital variation in adherence to diagnosis, treatment, and follow-up guidelines for several malignancies due to both patient-specific and hospital-specific characteristics, including cancer type, availability of multidisciplinary consultation, and hospital region. [30] [31] [32] [33] Because the NCI-CC designation requires a robust research program, patients with AML who are treated at NCI-CCs may have increased access to clinical trials with novel agents beyond the standard of care. Prior studies that have evaluated the impact of clinical trial enrollment on mortality in patients with cancer found an improvement in lower overall and cancer-specific mortality among common cancer sites. [34] [35] [36] This access to clinical trials may contribute to the improved outcomes noted among patients with AML who are treated at NCI-CCs. This may be especially relevant in individuals with AML, in whom molecular discoveries and the development of targeted therapies have led to the recent approvals of several new drugs based on survival improvements demonstrated in clinical trials. 37 Patients treated at NCI-CCs had higher rates of renal failure and lower rates of respiratory failure and sepsis. Prior studies have noted renal failure to be a known complication in patients with acute leukemias. 38 We speculate that patients at NCI-CCs had higher rates of renal failure due to the potential administration of nephrotoxic drugs, such as novel agents or antimicrobials. The higher rates of leukapheresis we observed at NCI-CCs suggests that patients treated at NCI-CCs may have higher white blood cell counts, which is known to be a risk factor for kidney dysfunction. 39 Renal failure was associated with higher early mortality, but these associations did not differ by location of care. However, patients treated at NCICCs who experienced respiratory failure did have lower early mortality compared with those with respiratory failure who were treated at non-NCI-CCs. The higher patient volume at NCI-CCs may result in the improved recognition and management of common clinical sequelae of AML treatment such as renal and respiratory failure.
There are several limitations to the current study. Selection bias was introduced because we included only those patients who received chemotherapy and did not include patients who received treatment only in the outpatient setting. We did not have information regarding the specific type of chemotherapy given or whether patients were treated on clinical trial protocols at NCICCs. Although this may have contributed to the differences in outcomes we observed, we speculate that the majority of patients were treated similarly because induction chemotherapy for AML has not changed significantly over the last 40 years despite more recent trends in the use of hypomethylating agents for older patients. 40 We did not have details regarding important prognostic and predictive factors, including laboratory and molecular data, to consider in our early mortality and propensity analyses. As a result, there is likely to be some residual confounding from the imbalance in baseline characteristics among patients treated at NCI-CCs versus non-NCI-CCs. Similar to prior studies, 41, 42 we observed differences in the baseline characteristics of patients treated at NCI-CCs, specifically that they were younger, of white or Asian race, lived in more affluent neighborhoods, and had fewer comorbidities. However, after using propensity score methodology, which reduced the standardized mean differences to <10% for most variables, the early mortality benefit associated with NCI designation persisted. Therefore, it is less likely that the differences in these patient characteristics could solely account for the differences noted in outcomes.
Despite these limitations, the current study included a large and diverse patient population with findings that are representative of contemporary treatment and health care delivery among patients with AML at the population level. The use of these large administrative databases provided the statistical power with which to identify disparities in early mortality that could have implications for cancer care and delivery.
The current large, population-based study in hospitalized adult patients with AML demonstrated a significant reduction in early mortality associated with care at an NCI-CC. This difference persisted even after consideration of differences in the rates of and outcomes after complications and sociodemographic factors. This finding suggests potential disparities in the effectiveness of care for patients with AML across treatment facilities, and reinforces the need to further evaluate and measure how care is delivered to improve outcomes in all care settings.
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